Antimicrobial peptides (AMPs) are molecules that act in a wide range of physiological defensive mechanisms developed to counteract bacteria, fungi, parasites and viruses. Several hundreds of AMPs have been identified and characterized. These molecules are presently gaining increasing importance, as a consequence of their remarkable resistance to microorganism adaptation. Carbohydrate-binding modules (CBMs) are non-catalytic domains that anchor glycoside hydrolases into complex carbohydrates. Clostridium thermocellum produces a multi-enzyme complex of cellulases and hemicellulases, termed the cellulosome, which is organized by the scaffoldin protein CipA. Binding of the cellulosome to the plant cell wall results from the action of CipA family 3 CBM (CBM3), which presents a high affinity for crystalline cellulose. Here CipA family 3 CBM was fused to four different AMPs using recombinant DNA technology and the fusion recombinant proteins were expressed at high levels in Escherichia coli cells. CBM3 does not present antibacterial activity and does not bind to the bacterial surface. However, the four recombinant proteins retained the ability to bind cellulose, suggesting that CBM3 is a good candidate polypeptide to direct the binding of AMPs into cellulosic supports. A comprehensive characterization of the antimicrobial activity of the recombinant fusion proteins is currently under evaluation.
AMPs are cationic molecules with a wide range of antimicrobial activities, which vary from bacteria to fungi, parasites and viruses. These molecules have been recognized as an important component of the non-specific host defense system and innate immunity of all animal classes, including insects, amphibians and mammals [1] . Several hundreds of AMPs have already been identified and characterized (http://www.bbcm.units.it/$tossi). These molecules represent very appealing new tools for fighting infection, since microorganisms do not easily develop resistance mechanisms against their mode of action as it has been described for other types of antimicrobial compounds. This is probably due to the particular capacity of AMPs to bind and disrupt cellular membranes. It is well recognized that mutations in the genetic information encoding the overall plasma membrane structure and which may counteract the action of AMPs are less likely to occur than variations in the enzyme physiology within a host cell [2] .
In early studies involving AMPs, these molecules were obtained through purification from their original hosts or by chemical synthesis. This, of course, presented many restrictions to AMPs research mainly in what concerned the production of detectable quantities of the peptides. In recent years, many small cationic AMPs have been successfully produced using recombinant DNA methods in heterologous hosts [3] [4] [5] [6] , allowing the purification of larger quantities of the recombinant proteins. It is presently rec-ognized that producing cationic AMPs using recombinant techniques will accelerate research on their pharmaceutical potential and potential clinical application [6] . Many host cells have been selected for expression of AMPs but Escherichia coli has been established as one of the most popular recombinant bioreactors due to its fast growth rate and well-established expression systems [6] . Since AMPs are usually very small to be produced effectively individually, many authors aimed to express them in fusion with other molecules [3, [6] [7] [8] . Problems concerning low levels of expression, poor solubility, toxicity for the host cell, product proteolysis and poor recovery yields are usually overcome by the implementation of the fusion technology [9] .
Carbohydrate-binding modules (CBMs) 1 are non-catalytic domains present in glycoside hydrolases which target the associated catalytic modules to their substrates, therefore potentiating enzyme activity. Based on primary structure similarity, CBMs have been grouped into 50 sequence-based families (http://afmb.cnrs-mrs.fr/CAZY; February 2008). Structural studies on representatives of the majority of CBM families demonstrate that the topology of CBM ligand-binding sites complements the conformation of the target polysaccharide. Thus, in Type A modules, which interact with the flat surfaces of crystalline polysaccharides, such as cellulose, the binding site comprises a planar hydrophobic platform that contains three exposed aromatic amino acids [10] . In contrast, Type B CBMs, which bind to single polysaccharide chains, accommodate the ligands within extended clefts of varying depths [10] . In general, the capacity of CBMs to specifically recognize a range of polysaccharides has been shown to be pivotal in a range of biotechnological applications [11] .
The development of mechanisms for targeting bio-molecules to a diversity of matrixes is an emerging theme in biochemistry and biotechnology. In this work four different AMPs were fused to a family 3 CBM of CipA, a nonhydrolytic structural protein responsible for the assembly of Clostridium thermocellum multi-enzyme complex of cellulases and hemicellulases, termed the cellulosome [12] . The major goal of this approach was not only to promote the levels of expression of the selected AMPs in E. coli but also to develop a biotechnological tool that would allow fixing a variety of polypeptides, such as AMPs, onto cellulosic surfaces. Therefore, the immobilization of these fusion proteins in cellulosic supports will allow the generation of novel bio-products possessing antimicrobial properties. Cellulose is a safe and inert macromolecule and has excellent physical properties. In addition, it is cheap and commercially available in many different forms and has been approved for many pharmaceutical and human uses [11] .
Materials and methods

Cloning of the DNA sequence of CBM3 with a N-terminal linker
The gene encoding CBM3 fused to the endogenous CipA N-terminal linker sequence (LK) was isolated through PCR. The inclusion of the linker region in the encoding DNA sequence was envisaged to improve flexibility in the resulting fusion proteins. The DNA fragment encoding CBM3 and its N-terminal LK from C. thermocellum was amplified by polymerase chain reaction (PCR) from C. thermocellum YS genomic DNA with the thermostable DNA polymerase Pfu Turbo (Stratagene). The primers used were 5 0 -ACACCGACCAAGGGAGCAACA-3 0 (forward primer) and 5 0 -TTCTTTACCCCATACAAG AAC-3 0 (reverse primer). PCR was performed as follows: preheating at 95°C for 3 min, 25 cycles at 95°C for 20 s, 55°C for 30 s and 72°C for 30 s, followed by a final elongation period at 72°C for 10 min. The amplified product was recovered from a 1% agarose gel using the Gel Band Purification Kit (GE Health) and ligated into pMOSBlue (GE Health) to generate pCG1. The DNA insert of pCG1 was sequenced to ensure that no mutations had occurred during the PCR. This plasmid was used as template for the subsequent amplifications aiming at generating the fusion genes.
Cloning of the DNA sequences encoding the fusion proteins For these studies four cationic and amphiphilic peptides were selected: peptide-1 (LKLLKKL), peptide-2 (LKLL KKLLKLLKKLGGGK), peptide-3 (LKKLLKKLKKL LKK) and porcine myeloid antibacterial peptide-23 (PMAP-23) (RIIDLLWRVRRPQKPKFVTVWVR) [13] , as depicted in Table 1 . The nucleotide sequence of each peptide was engineered to allow codon optimization in E. coli. Sequences encoding the four peptides were included in the primers and fusion genes were generated through PCR, using the DNA polymerase FideliTaq (GE Health), utilizing plasmid pCG1 as template. The sequences of the primers used in this study for this particular aim are shown in Table 2 . Primers included NheI and XhoI restriction sites. To allow the sub-cloning of the gene encoding CBM3 fused to the linker sequence (LK-CBM3) into the expression vector, the DNA sequence encoding this truncated version of CipA was also amplified by PCR ( Table  2 ). The PCR reactions were performed as follows: preheating at 95°C for 2 min, 25 cycles at 95°C for 30 s, 55°C for 30 s and 68°C for 1 min, followed by a final elongation period of 68°C for 5 min. Amplified fragments were recovered from a 1% agarose gel using the Qiagen Gel Extraction Kit (Qiagen), ligated into plasmid pMOSBlue and sequenced to ensure that no mutations had occurred during the PCR. The generated recombinant plasmids were digested with NheI and XhoI and the excised products were cloned into expression vector pET21a (Novagen), pre-viously digested with the same restriction enzymes. This vector carries a T7lac promotor and the resulting recombinant proteins contained a C-terminal His 6 -tag to facilitate purification.
Expression of recombinants LK-CBM and fused proteins
To optimize expression of the various recombinant proteins, different growing and induction conditions were tested for a variety of recombinant E. coli strains. Below is a description of the optimized growing conditions obtained that allow the expression of each specific protein.
To express peptide-1 fused to LK-CBM3 (peptide-1-LK-CBM3) and peptide-3 fused to LK-CBM3 (peptide-3-LK-CBM3), E. coli Tuner (DE3) (Novagen) cells harboring the appropriate recombinant plasmids were cultured in Luria-Bertani broth (LB) containing 100 lg/mL ampicillin at 37°C to mid-exponential phase (OD 595 = 0.6). At this point isopropyl-b-D-thiogalactopyranoside (IPTG) was added to a final concentration of 0.2 mM and the cultures were incubated at 18°C and 30°C for 16 h, respectively. The proteins LK-CBM3 and PMAP-23-LK-CBM3, which results from the fusion of LK-CBM3 with PMAP-23, were expressed in E. coli BL21 (DE3) (Novagen) cells harboring the appropriate recombinant plasmids and cultured in LB containing 100 lg/mL ampicillin at 37°C to mid-exponential phase (OD 595 = 0.6). At this point IPTG was added to a final concentration of 1 mM and the cultures were incubated at 37°C for further 4 h. Peptide-2 in fusion with LK-CBM3 (peptide-2-LK-CBM3) was found to be insoluble when expressed by different E. coli strains under a range of induction conditions, which included inducing temperatures varying from 16°C to 37°C and IPTG concentrations ranging from 0.01 mM to 1 mM.
Purification of recombinant proteins
Recombinant E. coli cells were harvested by centrifugation at 7000g at 4°C for 15 min, resuspended in 20 mM Tris-HCl pH 7.0, 20 mM NaCl, 5 mM CaCl 2 (2H 2 O) (Buffer A) and disrupted by sonication on ice for 12 min. The resulting cell-free extracts were collected by centrifugation at 20,440g at 4°C for 30 min and the His 6 -tagged recombinant proteins purified by immobilized metal ion affinity chromatography (IMAC), using 5 mL Niquel Hi-Trap Columns (GE Health). The column charged with 0.1 M NiSO 4 was equilibrated with 20 mM Na 3 PO 4 , 500 mM NaCl, 40 mM Imidazole, pH 7.4. The cell extracts were loaded into the column which was washed with the equilibration buffer. Finally the recombinant proteins were eluted with 20 mM Na 3 PO 4 , 500 mM NaCl, 300 mM Imidazole, pH 7.4. After purification, proteins buffer were exchanged into Buffer A, using PD10-columns (GE Health). Purified proteins were analyzed by mass spectrometry and SDS-PAGE using 12% (w/v) acrylamide gels. Predicted sizes for the recombinant proteins were 22.1 kDa for LK-CBM3, 23.0 kDa for peptide-1-LK-CBM3, 24.1 kDa for peptide- 
Binding assays
Qualitative assessment of the binding of the recombinant proteins to Avicel (Sigma) was developed as follows: 100 lg of LK-CBM3, 50 lg of peptide-1-LK-CBM3, 50 lg of peptide-3-LK-CBM3 and 50 lg of PMAP-23-LK-CBM3, all in Buffer A, with 1% (v/
Bound and unbound fractions were analyzed by SDS-PAGE using a 12% (w/v) acrylamide gel. Controls containing protein but no polysaccharide were performed in parallel to ensure that no precipitation of the recombinant proteins occurred during the experiment (data not shown).
Antimicrobial assay
An antimicrobial assay for assessing the antibacterial properties of LK-CBM3 was implemented based on the procedures described in reference [14] . Briefly, 100 mL of LB were inoculated with colonies from an overnight culture plate of E. coli XL10 Gold (Stratagene) and grown at 37°C until OD 600 = 0.5. The cells (1 mL) were recovered by centrifugation at 3000g at 10°C for 10 min and the supernatant discarded. Cells were washed twice with 1 mL of Buffer A. Finally, bacteria were resuspended in 1 mL of the same buffer and serially diluted until 10 À4 . Precisely 150 lL of E. coli XL10 Gold 10 À4 were incubated with 150 lL LK-CBM3 at three different protein concentrations (0.1 mg/ mL, 1 mg/mL, and 2 mg/mL, all diluted in Buffer A). Several controls were incorporated in the experiment, including the incubation of the cells solely in Buffer A or with BSA at the same protein concentrations used for LK-CBM3. Cells were incubated under the various conditions at 210 rpm in an orbital incubator at 37°C for 2 h. At the end of the incubation period, 50 lL of each sample were plated onto LB agar plates and the number of bacterial colonies formed was counted after a 16 h incubation at 37°C. The remaining of the non-plated mixture was centrifuged at 13,000g at 4°C for 5 min and the supernatants used for protein quantitation using Bradford reagent [15] and analyzed by SDS-PAGE using a 14% (w/v) acrylamide gel.
Results and discussion
Expression and purification of recombinant LK-CBM and fused proteins
Four peptides, termed peptide-1, peptide-2, peptide-3 and PMAP-23 [13] , which details are presented in Table 1 , were fused with the family 3 CBM of CipA from C. thermocellum. The recombinant fusion proteins were engineered to contain an N-terminal AMP domain and a C-terminal His 6 -tag. Peptide-1, peptide-2, and peptide-3 are synthetic amphiphilic cationic peptides, which design was based on the studies provided by other authors [16, 17] . Similar molecules have already proved to have potent antimicrobial activity against Gram negative and Gram positive bacteria [16] . It has also been previously shown that peptides composed of both hydrophobic and hydrophilic residues, such as leucine (L) and lysine (K), present antimicrobial activity against E. coli and Staphylococcus aureus, both in the soluble form or immobilized into a water-insoluble non-degradable polymer support [17] . These apparently simple cationic peptides with proven detectable antimicrobial activity were selected to fuse with CtCBM3. In addition, a different peptide with antimicrobial activity, termed PMAP-23, was also selected for fusion with the carbohydrate-binding module [13] . This peptide derives from porcine myeloid cells, is highly cationic and also tends to form an amphipathic structure, typical of other antibacterial peptides [1] . Synthetic PMAP-23 showed antibacterial activity against Gram positive and negative strains but no lytic activity against human erythrocytes, which suggested a certain degree of selectivity in disrupting cell membranes [1, 13] . It has been suggested that PMAP-23 antibacterial activity results from the interaction of the peptide with the bacteria cell membrane, followed by bacteria membrane alteration [1, 13] .
Data presented in Fig. 1 confirms that all four recombinant fusion proteins were expressed in E. coli. However, only peptide-1-LK-CBM3, peptide-3-LK-CBM3, PMAP-23-LK-CBM3 and LK-CBM3 were expressed in the soluble fraction of E. coli, although as a result of several optimization experiments (results not shown). In contrast, peptide-2-LK-CBM3 formed inclusion bodies in E. coli and protein precipitation in vivo was persistent while using different E. coli expression strains and different growth and induction temperatures (Figs. 2 and 3) . To overcome the insolubility of some AMPs, as well as their cytotoxic properties, some authors expressed these peptides in E. coli in fusion with different protein partners, utilizing different expression systems. Therefore, SMAP-29 was expressed using the intein-mediated system [14] , the human b-defensin 2 with the thioredoxin expression system [3, 6] , Hal18 by fusion with baculoviral polyhedron protein [9] and LL-37 utilizing the glutathione. S-transferase fusion system [7] , among many other examples. In addition, enterocins A and B, which are bacteriocins from Enterococcus faecium, were produced in fusion with a microbial CBM, although the experiment aimed at developing an easier purification system for the recombinant proteins [18] . In general, the aim of these experiments was to develop a mechanism to produce at high levels the fusion protein in order to enhance the production of the AMP itself. Therefore, after purification of the fused proteins, a proteolytic digestion step using a specific protease is included in order to release the AMP in the purified form. In contrast with the above mentioned experiments, the aim of the work reported here was to obtain the AMPs fused with CtCBM3 as the final product. More than a mere fusion partner, CBM3 was used to target the AMP for cellulosic surfaces. Notwithstanding this major goal of the experiments, it can be anticipated that the expression and purification of the AMP fusion recombinant proteins was probably facilitated by the presence of CBM3 and the C-terminal His 6 -tag.
After optimizing expression in E. coli, the recombinant proteins were purified through IMAC. The data, presented in Fig. 4 , demonstrate that all proteins were purified from most E. coli contaminants and were obtained at high concentrations. Following the purification step, the proteins were buffer exchanged into Buffer A and their concentration calculated. Purified proteins presented final concentrations ranging from 0.5 mg/mL to 2.5 mg/mL. Mass spectrometry analysis confirmed the expected sizes and, therefore, the integrity of the four recombinant proteins, suggesting that the N-terminal AMP domain was not subjected to proteolysis in E. coli and during the purification steps.
Binding assays
CtCBM3 from CipA is a very well characterized and studied CBM [11, 12] and its three-dimensional structure has already been elucidated [12] . It is a Type A CBM, which means that it possesses a planar surface that interacts tightly with crystalline cellulose. CtCBM3 equilibrium affinity constant (K a ) for Avicel was reported to be 7.7 Â 10 6 M À1 [11] . To investigate whether the fusion of each of the four AMPs to CtCBM3 had some effect on its capacity to interact with crystalline cellulose, the capacity of the recombinant proteins to bind Avicel was evaluated. The data, presented in Fig. 5 , confirmed that all AMPs-LK-CBM3 retained capacity to bind Avicel, as revealed by the minor quantity of protein present in the unbound fraction and the resulting association of the recombinant protein with the carbohydrate fraction. Although a small quantity of LK-CBM3 was shown not to bind the structural carbohydrate (panel A, lane U), this phenomenon is certainly due to a relative excess of protein concentration in relation to the Avicel. In addition, the data also suggested that incorporation of His 6 -tag in the recombinant proteins had no effect in the capacity of the protein to bind cellulose. Taken together the results suggest that fusion of CBM3 with AMPs had no affect in cellulose-binding activity of the CBM, which makes the recombinant proteins potential candidates to target AMPs to cellulosic supports.
Evaluating the antimicrobial activity of CBM3
It has been reported that C-type lectins, another kind of carbohydrate-binding molecules, may present antimicrobial activity [19, 20] . Like CBMs, lectins are proteins that recognize carbohydrates and fulfill an important role in the immune system, which has been extensively studied over the last years. Lectins are well described but the understanding of the mechanisms by which they influence the immune responses is not well defined. However, it is believed that lectins are involved in the recognition of carbohydrates at cell surfaces [21] . To find out whether the recombinant LK-CBM3 itself would present antibacterial activity, an assay was performed against E. coli XL10 Gold cells (Stratagene). BSA was incorporated in this experiment as a control protein which does not possess recognizable antimicrobial activity. Both proteins were used at three different concentrations: 0.1 mg/mL, 1 mg/ mL, and 2 mg/mL. The data, presented in Table 3 , demonstrated that the numbers of CFU/mL are in the same range at all protein concentrations (LK-CBM3 and BSA) and had no variation when compared with the numbers of CFU following incubation with Buffer A. Therefore, the results suggest that LK-CBM3 did not affect the number of existing bacteria, confirming that this CBM does not present an antibacterial activity, in contrast to what has been described for C-type lectins [19, 20] . This observation is not particularly surprising in light of our present knowledge on the structure of Type A CBMs. It is well established that CtCBM3 has a ligand binding specificity restricted for crystalline cellulose. In addition, its planar binding surface is not effective for interacting with individual carbohydrate chains that are usually present on the microorganisms' surface glycoproteins, as lectins do. Therefore, structural constrains would preclude the interaction of the family 3 CBM with the bacterial cell surface. To confirm the inability of CBM3 to interact with the bacterial surface, LK-CBM3 and BSA were incubated with E. coli cells and bound protein was detected following cell centrifugation through the measuring of protein concentration in the supernatant. The data, presented in Table 4 , confirms that the two proteins have no capacity to attach to the bacteria surface since the concentration of LK-CBM3 recovered by centrifugation after incubation with bacteria equals the one recovered after the same incubation with Buffer A, for all initial protein concentrations (0.1 mg/mL, 1 mg/mL and 2 mg/mL). A similar result was observed for BSA incubation with E. coli XL10 Gold and Buffer A (columns C and D from Table  4 ). Although a small quantity of protein was lost from the initial concentration (for the protein concentrations of 1 mg/mL and 2 mg/mL), this was probably due to protein precipitation during the assays as it was also observed for the incubation with Buffer A. The supernatants used for protein quantitations were also analyzed by SDS-PAGE. The data, presented in Fig. 6 , confirmed that lack of binding was not associated with LK-CBM3 (lanes 1-3) and BSA (lanes 4-6) proteolytic degradation.
Conclusions
Here four AMPs were cloned and expressed in fusion with a family 3 CBM of C. thermocellum cellulosome. Expression occurred in the soluble form for three recombinants and protocols for purifying the recombinant proteins by IMAC were developed. CtCBM3 does not present detectable antimicrobial activity against E. coli XL10 Gold. Therefore, CBM3 is a good candidate polypeptide to direct binding of AMPs to cellulosic supports. Data presented here confirm that the fusion recombinants are now ready for further studies to measure and characterize their antimicrobial properties. Here it was shown that CBM3 may be attached to a non-related protein retaining its Escherichia coli XL10 Gold was incubated with LK-CBM3 and BSA at three different concentrations and then plated onto LB agar plates. CFU/ mL were calculated after a 16 h incubation at 37°C. The number of CFU/ mL for the experiment using exclusively buffer was 8 Â 10 2 . The values are average of three replicates. intrinsic biological activity [11] . It has also been confirmed that AMPs produced in E. coli fused to a CBM maintained their properties after purification and separation from the fusion partner [18] . Therefore, the perspectives that the fusion proteins obtained in this work can display intrinsic antimicrobial activity are good and it is anticipated that their antimicrobial potency should be comparable to the AMPs expressed individually. Further studies will proceed in the future aiming at quantifying the antimicrobial properties of the proteins reported here, both in solution or fixed into insoluble surfaces.
